Drug Profile
Trastuzumab biosimilar - Adello Biologics
Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Therapeutic Proteins International
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB 2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Breast cancer
Most Recent Events
- 03 Jan 2019 Kashiv Pharma acquired all the assets of Adello Biologics and changed its name to Kashiv BioSciences
- 16 Nov 2016 Therapeutic Proteins International is now called Adello Biologics
- 24 Jun 2015 Discontinued for Breast cancer in USA (unspecified route)